Toma et al., 2012 - Google Patents
Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspectsToma et al., 2012
View HTML- Document ID
- 7582217886715477089
- Author
- Toma I
- McCaffrey T
- Publication year
- Publication venue
- Cell and tissue research
External Links
Snippet
Age-related progression of cardiovascular disease is by far the largest health problem in the US and involves vascular damage, progressive vascular fibrosis and the accumulation of lipid-rich atherosclerotic lesions. Advanced lesions can restrict flow to key organs and can …
- 102000004887 Transforming Growth Factor beta 0 title abstract description 224
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Toma et al. | Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects | |
Goumans et al. | TGF-β signaling in control of cardiovascular function | |
Budi et al. | TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities | |
Schwartz et al. | The intima: soil for atherosclerosis and restenosis | |
Dookun et al. | Therapeutic potential of senolytics in cardiovascular disease | |
Buhl et al. | The role of PDGF-D in healthy and fibrotic kidneys | |
Suwanabol et al. | Transforming growth factor-β increases vascular smooth muscle cell proliferation through the Smad3 and extracellular signal-regulated kinase mitogen-activated protein kinases pathways | |
Borkham-Kamphorst et al. | The PDGF system and its antagonists in liver fibrosis | |
Tsai et al. | TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation | |
Lafyatis | Transforming growth factor β—at the centre of systemic sclerosis | |
Gharaee-Kermani et al. | Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFβ signaling and the myofibroblast | |
Aschner et al. | Transforming growth factor-β: master regulator of the respiratory system in health and disease | |
Akhurst et al. | Targeting the TGFβ signalling pathway in disease | |
Zalewski et al. | Vascular myofibroblasts: lessons from coronary repair and remodeling | |
Gu et al. | Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis | |
Carmeliet et al. | Transgenic mouse models in angiogenesis and cardiovascular disease | |
Pardali et al. | TGFβ signaling and cardiovascular diseases | |
Beyer et al. | Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling | |
Halwani et al. | Role of transforming growth factor–β in airway remodeling in asthma | |
Rayego-Mateos et al. | Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis | |
Fischer et al. | Anti-PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels | |
Lupieri et al. | Smooth muscle cells-derived CXCL10 prevents endothelial healing through PI3Kγ-dependent T cells response | |
Ren et al. | Novel paracrine functions of smooth muscle cells in supporting endothelial regeneration following arterial injury | |
Joshi et al. | Coagulation‐driven platelet activation reduces cholestatic liver injury and fibrosis in mice | |
Vandenbriele et al. | Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesis |